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Abstract. The aim of the present study was to establish the 
role of platelet‑activating factor acetyl hydrolase (PAF‑AH) 
in the resolution phase of gout using an established in vitro 
mononuclear cell model. The effects of signalling pathway 
inhibitors on PAF‑AH secretion, as well as the effects of 
the common treatments hydrocortisone and colchicine, an 
antibody against the anti‑inflammatory cytokine transforming 
growth factor β1 (TGFβ1), and the transcriptional inhibitor 
actinomycin D, were also investigated. The effect of recombinant 
PAF‑AH on cytokine secretion by these cells was also 
determined. Human peripheral blood‑derived monocytes were 
isolated and differentiated into macrophages. Monocytes and 
macrophages were stimulated with monosodium monohydrate 
urate (MSU) crystals or lipopolysaccharide in the presence 
or absence of AEG3482 [a c‑Jun N‑terminal kinase (JNK) 
inhibitor], MG132 (a proteasome inhibitor), hydrocortisone or 
colchicine. Cultures were then analysed for PAF‑AH secretion 
using ELISA. A 6‑fold upregulation of PAF‑AH secretion was 
observed following macrophage exposure to MSU crystals 
for 24 h (29.3±6 vs. 5.4±0.3 ng/ml unstimulated; P<0.05). 
Following 72 h, PAF‑AH levels decreased significantly 
(11.1±1.8; P<0.01). Secretion was further enhanced following 
pre‑treatment with the JNK protein kinase inhibitor AEG3482 
prior to MSU crystal stimulation (P<0.05) and was abrogated 
when cells were preincubated with actinomycin D or the 
proteasome inhibitor MG132 (50, 100 and 200 µM). The 
addition of recombinant PAF‑AH (2.5‑10 ng/ml) to MSU 
crystal‑stimulated immature monocyte cultures significantly 
decreased pro‑inflammatory interleukin (IL)‑1β (unstimulated 
687±124 vs. stimulated 113±30 pg/ml) and IL‑6 secretion 
(unstimulated 590±50 vs. stimulated 182±19 pg/ml). Treatment 
of MSU crystal‑stimulated macrophages with hydrocortisone 
(2 µM) also significantly decreased PAF‑AH release (P<0.05). 
Neutralising anti‑TGFβ1 addition decreased PAF‑AH 
dose‑dependently with the highest inhibition observed at 
1 µg/ml (P<0.05). The results implicated that PAF‑AH may 
have an anti‑inflammatory role in the resolution phase of gout.
Introduction
Gout was often referred to as an affliction of kings due to its 
association with a lavish diet and excess alcohol consumption. 
In fact, Henry VIII was reported to have suffered from 
gout (1). The last few decades has seen a global rise in new 
patient diagnoses (2) and the prevalence of the disease has 
increased particularly in the UK (3). Gout is an inflammatory 
form of crystalline arthritis characterised by the deposition 
of excess circulating uric acid in the form of monosodium 
monohydrate urate (MSU) crystals into intra‑articular joints 
and tissue spaces (4). Patients experience recurrent acute 
flares of severe joint inflammation. Such attacks involve 
inflammation caused by the interaction between MSU crystals 
and the local tissue environment including intra‑articular cells, 
monocytes and macrophages. The active stage of gout is defined 
by an inflammatory innate response involving monocytes 
and neutrophils. This response is driven in part by NLRP3 
inflammasome activation via NOD‑like receptors which 
activate interleukin‑1β (IL‑1β) release (5‑7). Studies in vitro 
suggest that MSU crystals may induce tumour necrosis factor α 
(TNFα), IL‑1β, IL‑6, platelet‑activating factor (PAF) secretion 
in undifferentiated monocytes which in turn may promote 
endothelial E‑selectin expression and secondary neutrophil 
adhesion (8‑10). Conversely, differentiated macrophages are 
able to uptake MSU crystals and release transforming growth 
factor β1 (TGFβ1), a powerful inhibitor of inflammation (11).
Therapeutic options for gout management remain limited to 
the use of anti‑inflammatory treatments such as non‑steroidal 
anti‑inflammatory drugs (NSAIDs), IL‑1β antagonists, adre‑
nocorticotrophic hormone (ACTH), colchicine, allopurinol, 
or hydrocortisone injections following acute flares. A study 
reviewing patients with tophaceous gout and the risk of compli‑
cations reported that for all patients there was at least a 
25% casual risk of arterial hypertension, hyperlipidaemia, 
diabetes, renal function impairment and cardiovascular issues. 
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Even after treatment these patients had at least three gout flares 
per year (6,7). Mononuclear cells are a vital part of innate 
immunity and have been identified to secrete multiple enzymes 
into the microenvironment. However, information regarding 
the role of enzymes secreted in gout afflicted joints is limited. 
Recently published guidelines by the European League Against 
Rheumatism have highlighted the potential of enzymes such as 
febuxostat (xanthine oxidase inhibitor) and pegloticase (acts as 
an uricase) which target uric acid metabolism, as therapeutic 
agents in gout (12,13).
Platelet‑activating factor acetyl hydrolase (PAF‑AH) 
has multiple roles in numerous pathologies and synthesis 
and secretion of PAF‑AH are increased during monocyte to 
macrophage differentiation (14‑16). Two PAF‑AH isoforms 
have been identified; plasma PAF‑AH and intracytoplasmic 
PAF‑AHII. Plasma PAF‑AH is a polypeptide with molecular 
weight 40 kDa, mostly produced by macrophages and 
hepatocytes. It is an anti‑inflammatory enzyme since it is 
predominantly involved in degrading inflammatory phospho‑
lipids and is found mainly bound to low density lipoprotein 
(LDL) in the circulation (17‑19). Plasma PAF‑AH deficiency 
has been linked to inflammatory reactions such as sepsis, 
cardiovascular disease and anaphylaxis (20,21).
PAF‑AH resolves inflammation through the inactivation 
of PAF, a potent, inflammatory lipid mediator. Serum PAF 
concentrations are rigorously controlled by tight regulation 
of synthesis and degradation. The acetyl sn‑2 group on the 
backbone of PAF is required for biological activity and is the 
target for PAF‑AH action via esterification converting PAF 
to its inactive lysosomal‑PAF form (22). We have previously 
shown that immature monocytes pre‑treated with recombi‑
nant PAF‑AH showed a dose‑dependent inhibition of TNFα 
synthesis (12). The mechanism by which PAF‑AH is regulated 
is still not fully understood and so we have investigated the 
effect of common gout therapeutics on PAF‑AH expression. 
The aim of this study was to investigate the effect of MSU 
crystal stimulation on macrophage PAF‑AH secretion in vitro 
and to determine the factors and pathways that may be involved 
in this process.
Materials and methods
Materials. Hydrocortisone (HC) actin D, lipopolysaccha‑
ride (LPS) Dulbecco's modified Eagle medium (DMEM), 
dimethyl‑ethyl‑sulphonyl‑oxide, HANKS balanced salt solu‑
tion, histopaque, phosphate buffer saline (PBS), Colchicine 
and methanol were purchased from Sigma Aldrich, Poole, UK. 
Proteasome inhibitor (MG132) and c‑Jun N‑terminal kinase 
(JNK) inhibitor (AEG3482) were purchased from Tocris 
Bioscience UK. Cyclic adenosine monophosphate inhibitor 
(cAMPi) and MSU crystals were purchased from Enzo Life 
Sciences, Germany. Monoclonal mouse IgG1 clone 9016, mouse 
anti‑human TGFβ1 (MAB240), recombinant PAF‑AH, IL‑1β 
and IL‑6 ELISA kits and cell lysis solution were purchased 
from R&D Systems, Abingdon, UK. Manufacturer's instruc‑
tions were followed for all listed kits and reagents. Mouse 
anti‑human IgG1 monoclonal antibody (MAB3832) was used 
at 100 µg/ml, mouse anti‑human CD163 IgG1 monoclonal 
antibody (clone 215927) was used at 2.5 µg per 105 cells and 
were both purchased from R&D Systems, Abingdon, UK. Goat 
ant‑human IgG whole molecule FITC was used at a 1:64 dilu‑
tion in PBS and purchased from Sigma, Aldrich, Poole, UK.
Monocyte and macrophage preparation. The present study 
incorporated a series of in vitro cell cultures of differentiated 
monocytes isolated from human blood cones purchased from 
the National Health Service Blood Bank (Colindale, London, 
England). Ethical approval was granted by the Middlesex 
University Institutional Ethics Committee, Department 
of Natural Sciences (London, England) and this was also a 
purchase requirement from the blood bank. The present study 
complied with the ethical standards established in 1964 in the 
Declaration of Helsinki.
Leucocyte rich blood cones and blood group AB positive 
serum were purchased from the NHS Cord blood and transplant 
bank (Colindale, London, UK). The cones were washed with 
PBS to and centrifuged on histopaque at 620 x g for 20 mins 
to harvest leucocytes. The monocyte enriched fraction was 
obtained from the interface, washed in HANKS balanced 
solution without calcium or magnesium, after which cells 
were counted and cultured into 24 well plates at 4x106 per 
ml in DMEM containing 1% penicillin and streptomycin at 
37˚C in an atmosphere containing 5% CO2. The mononuclear 
cells were allowed to adhere for 1 h at 37˚C after which any 
non‑adherent cells were removed by aspiration and washing 
with PBS. The adherent cells were then cultured in Dulbecco's 
media containing 10% AB serum either for seven days to obtain 
macrophages or overnight for use as monocytes (9‑11). These 
methods were established previously and macrophage differen‑
tiation was determined by light microscopy and flow cytometry 
phenotypic analysis using the macrophage differentiation 
Figure 1. Time course of PAF‑AH production. Results are presented as the 
mean and standard deviation of 3 similar experiments. Peak PAF‑AH release 
was detected at 24‑48 h followed by a decline in enzyme release following 
48 h. A significant increase in PAF‑AH was detected at 24 h when compared 
to 3.5 h following macrophage MSU crystal stimulation. *P<0.05 and 
***P<0.001 vs. Media. PAF‑AH, platelet‑activating factor acetyl hydrolase; 
MSU, monosodium monohydrate urate crystals.
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marker CD163 (10). Cell culture media changes were carried out 
at days 1, 3, 5 and 7 days of culture replacing with fresh DMEM 
containing 10% AB serum.
Differentiated macrophages were stimulated with LPS, 
(10 µg/ml) or MSU crystals (0.5 mg/ml) with or without 
pre‑treatment for 30 min with HC (1, 2 and 4 µM) Stimulation 
was stopped after 24 h of incubation in all experiments. 
The 0.5 mg/ml MSU concentration and time point (24 h) 
was used for all experiments since this concentration and 
time point were previously identified as optimum conditions 
from previous studies of mononuclear and macrophage cell 
stimulation (10‑13).
Macrophage stimulation. Macrophages were stimulated MSU 
crystals (0.5 mg/ml) or LPS (10 µg/ml) with or without pre‑treat‑
ment for 30 min at 37˚C. This was followed by the addition of 
pathway inhibitors: AEG3482, a JNK inhibitor (12.5, 25 and 
50 µM), MG132 a proteasome inhibitor (50 and 100 µM), actin D 
(2 µM). Incubation was stopped after 24 h in all experiments.
Treatment with colchicine or hydrocortisone or anti‑TGFβ1. 
Colchicine was prepared by dissolving in 1 ml ethanol as 
recommended by manufacturer's instructions. Further dilu‑
tions were carried out in DMEM media at concentrations 
of 125, 250 or 500 µg/ml. Hydrocortisone was dissolved in 
1 ml DMEM and further diluted in media to concentrations 
of 1, 2 and 4 µM. Mouse anti‑TGFβ1 and an isotype matched 
control IgG1 were both dissolved in PBS and used at 2.5, 5, 
10 ng/ml (anti‑TGFβ1) and 10 µg/ml (control IgG1) respec‑
tively. Macrophages were pre‑incubated with colchicine, 
hydrocortisone, anti‑TGFβ1 or IgG1 control for 30 min prior 
at 37˚C to addition of MSU crystals for 24 h after which super‑
natants were collected and analysed for PAF‑AH content.
Monocyte st imulation with recombinant PAF‑AH. 
Recombinant PAF‑AH was dissolved in 0.5 ml of PBS and 
further diluted in DMEM media (2.5‑10 ng/ml). Freshly 
isolated monocytes were pre‑treated with recombinant 
PAF‑AH for 20 min prior to the addition of MSU crystals and 
then incubated at 37˚C for 24 h after which supernatants were 
collected for cytokine analysis.
Enzyme linked immunosorbent assays (ELISAs). IL‑1β and IL‑6 
concentrations in cell culture supernatants were determined by 
sandwich ELISA using matched antibodies (DuoSet: R&D 
Systems, Abingdon, UK). PAF‑AH levels were determined 
using a solid phase quantikine ELISA (DPLG70 from R&D 
Systems) with sensitivity (0.8‑50 ng/ml) in conditioned cell 
culture supernatants. All samples were measured in duplicates 
using manufacturer's instructions without any deviations. 
Results were expressed as the mean ± SEM cytokine 
concentration (ng/ml) from at least 4 experiments.
Statistical analysis. All samples were measured in duplicate 
from at least three experiments, with results expressed as the 
mean ± standard deviation. Statistical analysis was carried 
out by applying one‑way analysis of variance with Dunnett's 
post hoc test or Student's t‑test where appropriate. P<0.05 was 
considered to indicate a statistically significant difference. 
All data were analysed using Excel (2016 version; Microsoft 
Corporation, Redmond, WA, USA).
Results
PAF‑AH secretion by MSU crystal stimulated macrophages. 
MSU crystal stimulation resulted in the upregulation of 
PAF‑AH secretion by in vitro differentiated macrophages 
compared to unstimulated macrophages. Peak enzyme release 
was detected at an incubation time of 24‑48 h which was 
approximately six‑fold higher than unstimulated macrophages 
(mean ± SD; 29.3±6.3 ng/ml vs. 5.36±0.3 ng/ml respectively, 
P<0.001) after which a decline in enzyme secretion occurred 
with levels reverting to near baseline levels after 72 h (Fig. 1).
Effect of hydrocortisone, colchicine, LPS, anti‑TGFβ1 and 
pathway inhibitors on macrophage PAF‑AH secretion. 
Figure 2. Effect of hydrocortisone and colchicine on PAF‑AH secretion 
by macrophages stimulated with MSU crystals or lipopolysaccharide. 
Differentiated macrophages were pre‑treated with HC (1‑4 µM) for 30 min 
prior to the addition of (A) 0.5 mg/ml MSU crystals or (B) 10 mg/ml LPS and 
(C) 0.5 mg/ml MSU crystals and colchicine for 24 h. Collected supernatants 
were analysed for PAF‑AH by ELISA. Comparisons between macrophages 
in media only with MSU or LPS stimulation were significantly different. 
Macrophage MSU crystal‑but not LPS‑stimulated PAF‑AH secretion was 
significantly decreased in the presence of HC at all doses tested. The results 
are presented as the mean ± standard error of the mean. **P<0.01 vs. Media; 
##P<0.01 vs. MSU alone. PAF‑AH, platelet‑activating factor acetyl hydrolase; 
HC, hydrocortisone; MSU, monosodium monohydrate urate crystals.
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Co‑incubation of macrophages with hydrocortisone (1‑4 µM) 
significantly decreased MSU crystal stimulated PAF secretion 
(Fig. 2A). Interestingly, LPS‑stimulated macrophages also 
release PAF‑AH after 24 h of LPS stimulation. However when 
we added equivalent concentration of HC to LPS stimulated 
macrophages we did not observe a significant decrease in 
PAF‑AH secretion (Fig. 2). Also colchicine did not signifi‑
cantly alter the levels of PAF‑AH at the doses used. In the 
next stage of our investigation we tested a variety of pathway 
inhibitors to investigate the signalling mechanisms involved 
in this model. Notably, the JNK inhibitor AEG3482 did not 
decrease MSU crystal‑mediated PAF‑AH secretion. In fact, 
PAF‑AH release was enhanced following incubation with this 
inhibitor (Fig. 3). Inclusion of a proteasome inhibitor to the 
cultures significantly reduced PAF‑AH release at the doses 
used (Fig. 4). In contrast, PAF‑AH secretion was not signifi‑
cantly altered by the addition of cyclic AMP inhibitor (Fig. 5) 
implying that this mode of intracellular signalling was not 
involved in MSU‑mediated PAF‑AH secretion. The addition 
of actin D into the co‑cultures resulted in complete ameliora‑
tion of PAF‑AH detection in this pathway as seen in Fig. 4 
suggesting that MSU crystal de novo synthesis of PAF‑AH is 
required in macrophages. Addition of neutralising anti‑TGFβ1 
resulted in a dose dependent reduction in PAF‑AH at concen‑
trations of 0.25, 0.5 and 1 µg/ml whereas an isotype matched 
IgG control antibody at the same concentrations had no effect 
on PAF‑AH secretion (Fig. 5).
Trea t men t  wi th  recom bin a n t  PA F‑A H inh ib i t s 
pro‑inflammatory cytokine secretion by immature monocytes 
stimulated with MSU crystals. We investigated whether the 
activity of recombinant PAF‑AH could also modify IL‑1β and 
IL‑6 secretion. Previously, we had reported that recombinant 
PAF‑AH decreases TNFα cytokine secretion from immature 
human monocytes in a similar experimental model (9).
Pre‑treatment of undifferentiated, inflammatory mono‑
cytes with recombinant PAF‑AH at doses of 2.5, 5 and 10 ng/ml 
and then MSU crystals for 24 h resulted in a dose dependent 
decrease in IL‑1β and IL‑6 secretion. The highest inhibition 
was achieved at 10 ng/ml recombinant PAF‑AH (P=0.02 for 
IL‑1β and P=0.003 for IL‑6 respectively, Fig. 6).
Discussion
To the best of our knowledge this is the first study to 
identify that macrophage uptake of MSU crystals leads to 
an upregulation in secretion of the enzyme PAF‑AH. Little 
is known about the enzymes involved in the inflammation 
resolution phase of gout with research focussing mainly on 
caspase‑1 activating NALP3 (23,24). PAF‑AH is actually an 
anti‑inflammatory phospholipase that is found as a plasma 
isoform complexed mainly with LDLs (25). Low levels of 
PAF‑AH seem to correlate with a number of modalities. A 
study involving patients with acute allergy reactions reported 
that those patients with the lowest levels of plasma PAF‑AH 
were at high risk of severe anaphylaxis (26). Also, mast cells 
derived from rat bone marrow secrete PAF‑AH upon direct 
IgE activation indicating PAF‑AH may have a potentially 
crucial function in pathological and physiological defence. 
It is postulated that the likely function of PAF‑AH may be 
as a safety biosensor during inflammation. This is due to its 
ability to neutralise the effects of inflammatory PAF and 
oxidised phospholipids which are upregulated in pathologies 
such as thrombosis, allergy, sepsis as well as gout (26,27). 
A local increase in harmful lipids often accompanies 
sustained inflammation. Thus upregulation of PAF‑AH takes 
place in cells to deactivate and degrade PAF. In fact joint 
inflammation in gout is accompanied by a local increase in 
PAF, prostaglandin E2 and leukotrienes (28,29). In this study 
we have demonstrated that recombinant PAF‑AH treatment 
Figure 4. Effect of inhibitors on PAF‑AH secretion by macrophages. 
Following MSU crystal stimulated macrophage pre‑treatment with inhibitors 
downregulation of PAF‑AH secretion was observed; for actin D (P=0.002), 
and the proteasome inhibitor MG132 at 50 µM (P=0.08) and at 100 µM 
(P=0.01). The inclusion of cAMPi at a concentration range of 12.5, 25 
and 50 µM did not exhibit any significant changes in PAF‑AH production 
when compared with MSU crystal stimulated macrophages. **P<0.01 and 
***P<0.001 vs. Media. Results are expressed as the mean ± standard expres‑
sion of 3 repeated experiments. PAF‑AH, platelet‑activating factor acetyl 
hydrolase; actin D, actinomycin D; cAMPi, cyclic adenosine monophosphate 
inhibitor; MSU, monosodium monohydrate urate crystals.
Figure 3. Effect of the c‑Jun N‑terminal kinase inhibitor, AEG3482, on 
PAF‑AH release. The results revealed an upregulation of PAF‑AH following 
the addition of the AEG3482 inhibitor to macrophages stimulated with MSU 
crystals in which a two‑fold increase was observed by enzyme detection with 
50 µM AEG3482. Results are expressed as the mean ± standard deviation 
of 3 similar experiments. **P<0.01 vs. Media. PAF‑AH, platelet‑activating 
factor acetyl hydrolase; MSU, monosodium monohydrate urate crystals.
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may tip the inflammatory balance in favour of inflammation 
resolution as it was able to decrease monocyte derived IL‑1β 
and IL‑6 secretion due to MSU crystal stimulation. These 
results are consistent with our previous study in which PAF 
was upregulated by monocytes in response to MSU crystals (9) 
and recombinant PAF‑AH administration downregulated 
TNFα secretion. The exact form of PAF was not characterised; 
we propose that this was probably inert lysosomal PAF. 
Physiologically PAF‑AH functions on active PAF, converting 
it into lysosomal‑PAF (the inert form of PAF). Active PAF is a 
potent lipid intermediate that has immunomodulatory effects 
and a pivotal role in the pathogenesis of inflammatory disorders 
such as cardiovascular disease rendering this molecule 
inactive is important in healing (30). Given this function, it 
is not surprising that administration of exogenous PAF‑AH to 
animals with systemic inflammatory response syndromes or 
sepsis resulted in decreased leukocyte accumulation as well 
as pro‑inflammatory cytokine levels and increased bacterial 
clearance in septic mice. Indeed PAF‑AH enhances sepsis 
clearance by hydrolysing acetyl groups attached to other lipid 
substrates besides PAF (31,32). This function of the enzyme 
in neutralising inflammatory mediators could be particularly 
crucial in inflammatory gout joints in which a number of 
lipid mediators such as Prostaglandin E2 and PAF have been 
located (28). In endotoxaemic rats, an upregulation of plasma 
PAF‑AH was accompanied by a direct increase in ability to 
inactivate PAF and oxidised phospholipids (33).
We discovered that blocking TGFβ1 activity using a 
neutralising antibody resulted in a dose dependant decrease in 
PAF‑AH secretion. The anti‑inflammatory activity of TGFβ1 
is well established in gout inflammation resolution (13). Our 
results suggest that this effect may be attributed in part by the 
upregulation of PAF‑AH. Essentially both PAF‑AH and TGFβ1 
share a transcription binding site involved in macrophage 
regulation, mediating effects through canonical Sp1 (16,34). 
Hydrocortisone is known for its anti‑inflammatory properties 
through suppression of vascular permeability, vasodilation and 
leukocyte migration into inflamed sites (35). Unexpectedly 
in our study hydrocortisone decreased PAF‑AH secretion 
by MSU crystal stimulated macrophages. However, there is 
evidence that hydrocortisone may also have pro‑inflammatory 
properties. For example, hydrocortisone can interact with 
anti‑inflammatory drugs such as aspirin hydrolysis where it 
mediates esterase activity (36). Furthermore, when normal 
subjects were injected with 300 mg of hydrocortisone, there 
was an increase in toll like inflammatory receptor 2, 5, 9, high 
mobility group box‑1 and matrix metalloproteinase‑9 expres‑
sion occurred (37). Perhaps the long term use of hydrocortisone 
therapy in gout or arthritis could result in inadvertently driving 
the inflammatory response rather than limiting it.
Co‑incubation of MSU‑stimulated macrophages with the 
proteasome inhibitor MG132 resulted in a significant decrease 
in PAF‑AH secretion. This suggests that this pathway involves 
protein degradation (38). Conversely, colchicine had no signifi‑
cant effect. Colchicine is routinely prescribed as a prophylactic 
treatment for gout at similar doses tested in our study. It has 
recognized, powerful anti‑inflammatory properties in gout 
affecting cytokine levels; increasing levels of TGFβ1, prosta‑
glandins and lowering pro‑inflammatory factor levels (39).
Our results could be relevant to other arthropathic 
disorders such as rheumatoid arthritis (RA) as well as gout. 
Recently, it has been shown that PAF‑AH levels are signifi‑
cantly decreased in the sera of RA patients with active disease 
highlighting that PAF‑AH probably plays a protective role in 
the development of RA (40). Moreover analysis of the hyper‑
coagulable state in RA patients showed significant reduction 
in anti‑inflammatory serum PAF‑AH along with a decrease 
in IL‑4 and IL‑10 but a rise in inflammatory mediators 
such as IL‑6, IL‑17 and PAF (41). Therefore future studies 
should examine the expression profile of PAF‑AH levels in 
Figure 6. Downregulation of IL‑1β and IL‑6 by recombinant PAF‑AH in 
immature monocytes stimulated with MSU crystals. Inclusion of exogenous 
recombinant PAF‑AH resulted in a dose dependent reduction in IL‑1β release 
by monocytes. Statistical significance was observed at 5 ng/ml (IL‑1β, P=0.03; 
IL‑6, P=0.003) and at 10 ng/ml (IL‑1β, P=0.008; IL‑6, P=0.003) with respect 
to recombinant PAF‑AH pre‑treatment of macrophage cultures. Results are 
expressed as the mean ± standard deviation of at least 3 experiments. *P<0.05 
and **P<0.01 vs. MSU only. rPAF‑AH, recombinant platelet‑activating factor 
acetyl hydrolase; IL, interleukin; MSU, monosodium monohydrate urate 
crystals.
Figure 5. TGFβ1 is involved in macrophage PAF‑AH secretion upon 
MSU crystal uptake. Differentiated macrophages were cultured in media 
containing a neutralising antibody to TGF‑β prior to MSU crystal stimulation 
for 24 h and the collected supernatants were analysed for PAF‑AH by ELISA. 
Results are expressed as the mean ± standard deviation of at least 3 experi‑
ments. **P<0.01 vs. Media. TGFβ1, transforming growth factor β1; PAF‑AH, 
platelet‑activating factor acetyl hydrolase; IgG, immunoglobulin G; MSU, 
monosodium monohydrate urate crystals.
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the synovial fluid samples obtained from gout patients during 
active disease compared to quiescent joints. The efficacy of 
PAF‑AH treatment for gout patients should also be explored. 
In conclusion, we have demonstrated that PAF‑AH enzyme 
secretion is upregulated by macrophages following MSU 
crystal uptake and involves anti‑inflammatory TGFβ1. 
This research expands our understanding of an important 
anti‑inflammatory enzyme which could be functioning as a 
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